How ICER Underestimates High Cholesterol

December 10, 2020

The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists overlook the needs of high-risk patients – and underestimate the impact of high cholesterol.

View Graphic

Categorized in: Analysis

◀ Next Post

Previous Post ►